San Francisco, CA
Dr. Thierry Marie Jahan
A lung cancer specialist and Clinical Professor of Medicine at the University of California San Francisco, Dr. Thierry Marie Jahan is a graduate of George Washington University School of Medicine in Washington, D.C. Dr. Jahan is affiliated with the University of California San Francisco Medical Center where he specializes in the treatment of lung disease and lung cancers, including mesothelioma. He is the recipient of a number of awards for both his academic and scientific work and is the author and co-author of several academic publications. Currently, he also serves as Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology at UCSF.
Today, Dr. Jahan continues his work at the University of California San Francisco as a Clinical Professor of Medicine. He is dedicated to the treatment of mesothelioma, lung cancer, sarcomas and endocrine tumors with multiple treatment options. He also specializes in the study of new treatments for malignancies for illnesses related to the chest while continuing to care for his patients. His interests include new, state of the art molecular analyses and specifically designed drugs that target the disease precisely. This results in far fewer side effects, improved quality of life and longer life expectancy for those suffering with lung cancer and mesothelioma.
Main Specialty: Oncology
Other Interests & Specialties: General oncology, mesothelioma, non-small cell lung cancer, chest wall tumors, multimodal therapy, endocrine cancer, hematologic oncology, sarcoma and thoracic cancer.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Hematology, inducted into the Council of Master Clinicians by the UCSF Department of Medicine, Medical House Staff Outstanding Teacher Award, Friend of the Palliative Care Service Award, member of American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC), Association of Northern California Oncologists and the UCSF Helen Diller Family Comprehensive Cancer Center
Education & Experience:
- Residency in Internal Medicine at Cedars-Sinai Medical Center
- Fellowship in Hematology/Oncology at UCSF
- Fellowship in Internal Medicine at Cedars-Sinai Medical Center
- Medical Degree from George Washington University School of Medicine
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018; 36(13): 1343-1373. doi: 10.1200/JCO.2017.76.6394
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clinical Cancer Research. December 2014;20(23):5927-5936. doi: 10.1158/1078-0432
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. Jun 2012; 76(3): 393-396. doi: 10.1016/j.lungcan.2011.11.014
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. Journal of Thoracic Oncology. November 2011; 6(11):1857-64. doi: 10.1097/JTO.0b013e318229a41e
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery. December 2002;124(6):1183-1189. doi: 10.1067/mtc.2002.125817
Mesothelioma Clinical Trials by Thierry Marie Jahan, MD
Dr. Jahan is associated with the following clinical trials:
Conditions: Malignant Mesothelioma Last Updated: June 30, 2016 Status: Completed